Healthtech Startups

ArmasTec develops fabric exoskeletons for workers across industrial, hospitality, and healthcare sectors. The company aims to make wearable exoskeleton technology widely accessible for manual work across diverse industries.

1 investor

ARMGO develops a novel class of therapeutics called Rycals that target ryanodine receptors (RyRs) to correct calcium channel dysfunction in serious diseases with high unmet need. Its lead candidate, Surlorian, is being developed for heart failure by addressing an underlying driver of disease progression.

1 investor

ARMR Sciences is developing conjugate vaccines and biologic countermeasures, including its lead candidate ARMR-100, designed to bind fentanyl in the bloodstream and prevent overdose from synthetic drugs. It targets high-risk populations such as first responders, military personnel, and individuals in recovery, working on a platform approach to address emerging drug threats.</parameter> <parameter name="sector_codes">["biotech", "healthtech", "deeptech"]

1 investor

ARNA Genomics US develops liquid biopsy multiomics diagnostic technologies, with a current focus on ARNA Breast, an assay for early-stage breast cancer detection. The company operates as a research diagnostic laboratory conducting clinical trials on its cancer marker tests.

1 investor

Aroa Biosurgery Limited manufactures medical devices, including Endoform, for surgical applications with coverage under Medicare reimbursement policies.

1 investor

Arōe provides personalized, science-based preventative care and longevity services including nutrient IV therapy, personalized treatment plans, and lifestyle interventions for health optimization. The company serves individuals seeking proactive health management through in-person clinic visits and concierge services delivered to home or office locations.

1 investor

Arogya Finance provides medical loans to underserved populations in India using alternative risk assessment tools to finance patients outside the formal banking system. The company operates as a non-bank financial company serving individuals seeking treatment at hospitals of their choice.

1 investor

AROMICS develops functional genomics and proteomics technologies for research and development of new therapies and diagnostic products in human health. The company focuses on translational research, personalized medicine, and biomarker identification for the pharmaceutical and diagnostics industries.

1 investor

Aronora is a clinical-stage biotech developing antithrombotic therapies, including factor XI/XIa inhibitors and thrombolytic drug candidates, to treat and manage thrombotic and thromboembolic conditions such as acute ischemic stroke, heart attack, and pulmonary embolism. Its pipeline of cardio-hematology programs targets patients requiring time-sensitive thrombolytic intervention or management of thrombosis risk.

1 investor

Arosa provides in-home caregiving, nursing, and care management services to adults requiring support with activities of daily living and chronic disease management. The company operates across multiple U.S. regions and employs nurses, social workers, and care coordinators.

1 investor

Advanced Reconstructive Surgery Alliance (ARSA) is a physician practice management organization (MSO) that provides business support—including compliance, credentialing, finance, HR, IT, marketing, M&A, revenue cycle management, and research—to reconstructive and cosmetic surgery practices. It operates a national network of more than 80 physicians across multiple U.S. states under a "PrivAdemic" model combining private practice with academic collaboration.

1 investor

Arsipa is a group of occupational medicine and workplace safety providers offering companies preventive health services and safety management (Grundbetreuung and betriebsspezifische Betreuung per DGUV V2). It serves employers across Germany and Austria with on-site care through a network of local specialists.

1 investor

Artax Biopharma is a Phase 2 clinical-stage biotechnology company developing first-in-class oral small-molecule Nck modulators that target T cell receptor Signal 1 activation to treat autoimmune diseases without causing immunosuppression. Its lead candidate AX-158 has shown Phase 2a data in psoriasis, with additional Phase 2 trials planned in atopic dermatitis and rheumatoid arthritis.

1 investor

Arteryex combines blockchain and AI technology to leverage underutilized health data for personalized healthcare management and medical services. The company targets the Japanese healthcare market, aiming to address the gap between average lifespan and healthy lifespan through optimized health and medical solutions.

1 investor

ArtesRx is a behavioral health long-term care pharmacy organization that operates a network of community-based pharmacies serving patients with complex medication needs, particularly those managing mental illness and substance use disorders.

1 investor

Articulus Surgical develops minimally invasive surgical robotic systems designed for India's Tier 2 and Tier 3 hospitals, where infrastructure and space are constrained. The company builds patient and surgeon-centric robotic platforms optimized for resource-limited surgical environments.

1 investor

Artidis develops nanomechanical imaging technology for rapid cancer diagnosis and treatment optimization in clinical settings. The company's diagnostic platform aims to help clinicians with faster, more accurate cancer assessment and prognosis.

1 investor

Artielle Immunotherapeutics develops DRhQ, a therapeutic platform that targets the CD74 receptor and inhibits macrophage migration inhibitory factor (MIF) to treat neuroinflammatory conditions such as progressive multiple sclerosis and advanced cancers. The company builds on research from OHSU and the VA Portland Healthcare System.

1 investor

ArtiFex Medical develops vascular grafts made from bacterial cellulose for small-diameter vascular access. The company provides a biocompatible material solution for vascular applications in the medical device sector.

1 investor

ARTIS Ventures is a venture capital firm investing in frontier technologies and breakthroughs primarily at the intersection of technology, biology, and healthcare. The firm backs early-stage companies across biotech, life sciences, and health technology sectors, with a portfolio spanning therapeutics, digital health, and medical devices.

1 investor

SocialRx connects members with non-clinical, community-based activities in art, culture, nature, and movement to address mental health and loneliness. The company operates a social prescribing solution serving populations with barriers to traditional mental health care across the United States.

1 investor

Arul Health is building a patient navigation service that bridges healthcare and social care, helping people with serious diagnoses coordinate care, advocate on their behalf, and contest costs. It supports patients and their families through the practical and emotional challenges of illness.

1 investor

ARx makes a hands-free wearable headset for people with low vision or sight loss, using a camera that streams video in real time to AI-powered visual assistance apps and bone-conduction audio to describe objects, text, and surroundings. It targets users familiar with apps like Microsoft Seeing AI or Google Lookout who want to use them without holding a smartphone.

1 investor

Arxada develops microbial control and antimicrobial technologies for professional hygiene, paints, coatings, wood protection, home and personal care, and human health applications. The company serves industrial and consumer end markets with chemistry-based solutions that support product safety and performance.

1 investor